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Summary Sputum clearance is of prime importance in the management of patients
with bronchiectasis. While nebulised normal isotonic saline (0.9%) (IS) has been
anecdotally used to treat patients with tenacious sputum, the use of hypertonic
saline (7%) (HS) could have potential muco-protective and clearance properties.
24 patients with bronchiectasis were randomised to receive four single treatment
schedules in random order: (1) active cycle breathing technique (ACBT) alone, (2)
nebulised terbutaline then ACBT, (3) nebulised terbutaline, nebulised IS then ACBT
and (4) nebulised terbutaline, nebulised HS then ACBT.
Sputum weights were significantly higher after HS than IS (P ¼ 0:002). Ease of
expectoration also differed overall (P ¼o0:0001) and was significantly lower with
HS than with IS (P ¼ 0:0005). Sputum viscosity differed between treatment phases,
with a significant linear trend to reduced sputum viscosity with HS (P ¼ 0:0002).
These changes were associated with small but statistically significant differences in
FEV1 (P ¼ 0:043) and FVC (P ¼ 0:011) between treatment phases.
Nebulised hypertonic saline can be used safely and effectively as an adjunct
to physiotherapy in selected patients. A long-term prospective trial is now indicated
to determine its effectiveness on long-term infection rate, quality of life and
lung function.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
For patients with bronchiectasis sputum retention
is a distressing symptom and arguably the most
important factor in maintaining the vicious cycle of
respiratory infection, inflammation and further
sputum production. The use of nebulised ‘‘normal’’
0.9% isotonic saline (IS), as a method of enhancing
mucociliary clearance has become a clinically
accepted adjunct to physiotherapy in the treat-
ment of many chronic lung conditions but it has
little scientific evidence on which to base its use.
7% hypertonic saline (HS) is being increasingly used
in clinical practice,1 specifically for diagnostic
purposes in other lung conditions, but its use as a
mucolytic agent is poorly understood as there are
few published human studies which evaluate its
role in reducing sputum viscosity. The sodium and
chloride concentrations in sputum produced in
bronchiectasis are below those found in plasma
(hypotonic), and also below the optimum for ciliary
transportability of sputum.2 Administration of a
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hypertonic sodium chloride solution may increase
mucociliary clearance by influencing ciliary func-
tion, increasing the osmotic drive, altering the
visco-elasticity of sputum, and, therefore, reducing
the viscosity and aiding sputum clearance.
Sputum volumes in bronchiectasis patients vary
between 20 and 500mls per day but previous
physiotherapy studies have excluded patients who
produce less than 30 g per day.3 The aim of this
study was to evaluate nebulised 7% HS as an
adjunct to physiotherapy airway clearance techni-
ques in patients with stable bronchiectasis who
produce less than 10 g of sputum per day, and to
compare this with nebulised 0.9% IS and airway
clearance alone. Advances in diagnostic techniques
(high resolution CT scanning) allow patients to be
diagnosed much earlier in the disease process, and
we therefore see patients with minimal sputum
despite recurrent infections, despite having radi-
ologically established disease. This theoretically
allows the opportunity to institute treatment
earlier and the best chance of limiting disease
progression.
Methodology
Twenty-four consecutive patients, 17 females,
(5573.6 yrs) and 7 males (6473.8 yrs) with stable
newly diagnosed bronchiectasis, diagnosed by high
resolution CT scanning, who had not previously had
physiotherapy input were referred from chest
physicians to take part in the study. All of the
patients reported difficulty in expectorating ‘thick,
sticky’ sputum and had required at least one course
of antibiotics in the last 6 months (mean 1.8). Prior
to approaching the patients, consent for inclusion
was obtained from the patients by respective chest
physicians. Once consultant consent was obtained
patients were given a full written and verbal
explanation of the study. Written informed consent
was then obtained prior to the HS challenge test.
Ethical approval was obtained from the local
research ethics committee.
Allergic broncho-pulmonary aspergillosis and
cystic fibrosis phenotypes were excluded. Patients
were able to continue all routine medication
(inhaled/nebulised bronchodilators, long acting
bronchodilators, leukotriene antagonists, oral or
inhaled steroids) but were excluded if they had
been prescribed a course of antibiotics in the last
month or required antibiotics during the course of
the study.
To establish average daily sputum production
patients collected all daily expectorated sputum
for 7 days. This was all weighed ‘wet’ to determine
sputum production of less than 10 g. Non-isotonic
solutions may cause bronchospasm and subsequent
reduction in lung function. Prior to commencing the
study patients underwent a nebulised HS challenge
test and were to be excluded from the study if they
reported ‘chest tightness’, ‘wheeze’ or ‘difficulty
in breathing’, or had a 10% reduction in spirometry
following inhalation of HS. In fact there were no
patients excluded following the challenge test. One
male patient failed to attend for follow up, and was
therefore excluded, but complete data was avail-
able for the remaining 23 patients.
A cross-over study design was used with compu-
ter determined random allocation to four single
session treatment schedules. The patients
attended once weekly over a four week period
to complete all treatment schedules. Nebulised
terbutaline was used in phases (2, 3, 4) as a
premedication to minimize adverse effects.
Treatment schedules
(1) Active cycle breathing technique (ACBT) alone.
(2) Nebulised terbutaline followed by ACBT after
10min.
(3) Nebulised terbutaline followed after 10min by
nebulised isotonic saline (0.9%) then ACBT.
(4) Nebulised terbutaline followed after 10min by
nebulised hypertonic (7%) then ACBT.
IS and HS solutions were produced by the pharmacy
in blinded labeled sterile solutions. The phy-
siotherapist performing challenges and sputum
assessments remained blinded to IS and HS
throughout the study. Nebulisation of all solutions
was carried out in a supported upright position,
breathing at normal tidal volume and respiratory
rate for 5min.4 Patients performed ACBT immedi-
ately following nebulisation of both IS and HS as
time to maximum effect is not known. The ACBT, as
described by Pryor and Webber,5 was performed in
right and left side lying positions, as some patients
were unable to tolerate standard postural drainage
positions. It is recommended that treatment time is
adapted for each patient.6 For patients with a
moderate amount of sputum a minimum of 10min
in any one position is usually necessary. As treat-
ment was carried out in 2 positions a minimum
treatment duration of 10min and a maximum of
20min (mean 16min) was set for all patients. The
end point of treatment was standardized to be
when an effective huff to low lung volume in 2
consecutive cycles was dry sounding and unproduc-
tive. The four periods of treatment administration
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were separated by a ‘wash out’ period of 1 week to
enable the patients condition to return to a level
uninfluenced as far as possible by the treatment
previously received.
Outcome measures used in the study were; wet
sputum weight (grams), sputum viscosity (no
sputum production and pourability grades 1–4),
ease of expectoration visual analogue scale (VAS)
and spirometry (FEV1, FVC). All expectorated
sputum was weighed wet immediately following
each treatment phase. This was done using pre-
calibrated electronic scales. Measuring wet sputum
weight has been shown to be a reliable and valid
method of assessing sputum expectorated during
ACBT.7 The facilities were not available to measure
sputum viscosity using a rheometer and therefore a
viscosity pourability grading was used. A highly
significant correlation has been shown between this
pourability grade and sputum viscosity measured
using a rheometer.8 Spirometry was performed in
each treatment schedule 1 pre and post ACBT, 2 pre
nebulised terbutaline, post nebulised terbutaline
and post ACBT, 3 pre nebulised terbutaline, post
terbutaline, post IS and post ACBTand in schedule 4
pre nebulised terbutaline, post terbutaline, post
HS, and post ACBT.
Non-parametric analysis was used as the data
was not normally distributed and a significance
level of Po0:05 was used throughout. The
Friedman test assessed general, non-specified
differences across the interventions and between
individual treatments in each intervention group.
Results
There were significant differences in sputum
weight (Freidman T2 ¼ 36:15; Po0:0001) and ease
of expectoration visual analogue scores (Freidman
T2¼ 31.14, Po0:0001) and small but significant
differences in lung function tests (Table 1). Post hoc
multiple comparisons using contrasts suggested
significant differences between all comparison
groups except the bricanyl and IS groups.
Further analysis (by Wilcoxon, Chi2 and Mann–
Whitney tests) then revealed real differences
between all the intervention groups but the
findings from the IS and HS groups were of primary
interest. All but two patients produced more
sputum when treated with HS compared to IS
(z ¼ 0:377; P ¼ 0:0002) and although differences
were found between each intervention for ease of
expectoration, the lowest scores were recorded
following HS.
Sputum viscosity was analysed by comparing the
frequency of grades occurring in each of the 4
intervention groups. There was a significant overall
difference in the distribution of sputum viscosity
grades between the different treatment phases
(Chi2 ¼ 34:62 (12df), P ¼ 0:0005). Combination of
the categories of no sputum with grades 1 and 2,
and grades 3 with 4, confirmed this difference
(Total Chi2 ¼ 18:18 (3df), P ¼ 0:0004) and showed a
significant trend to higher grade of sputum viscosity
from ACBT through bricanyl, IS and HS treatment
phases (Chi2 for linear trend ¼ 13.46 (1df),
P ¼ 0:0002) (Table 2).
Eight patients had the same sputum viscosity
grade with IS and HS. However, 12 patients
increased by 1 grade and 3 patients by 2 grades;
no patients had a reduced grade. McNemars test
demonstrated that sputum grade was significantly
more likely to increase to grade 3 or 4 with HS than
with IS (Yates Corrected Chi2 ¼ 7:11 (1df),
P ¼ 0:008). These changes were associated with
small differences in FEV1 (P ¼ 0:043) and FVC
(P ¼ 0:011) between treatment phases, however,
there were no significant difference in FEV1
(P ¼ 0:12) or FVC (P ¼ 0:23) between IS and HS
treatments.
There was a significant difference in ease of
expectoration visual analogue scores between the
different treatment phases. Multiple comparisons
suggested significant differences between each
treatment phase, with lowest scores following HS
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Table 1 Summary results of sputum weight, ease of expectoration and spirometry in each treatment phase.
Sputum wt (g)
Median (IQR)
VAS (0–10)
Median (IQR)
FEV1 (l)
Median (IQR)
FVC (l)
Median (IQR)
ACBT alone 1.40 (0.88–3.30) 8.00 (6.18–9.40) 1.70 (1.21–2.19) 2.30 (1.58–2.70)
Terbutaline alone 2.75 (1.35–4.58) 7.70 (4.43–8.98) 1.80 (1.20–2.35) 2.60 (1.76–2.98)
IS (0.9%) 3.17 (1.45–6.25) 5.20 (2.75–8.38) 1.85 (1.36–2.20) 2.55 (1.91–2.94)
HS (7%) 5.3 (2.97–9.33) 2.40 (1.43–5.40) 2.00 (1.25–2.40) 2.50 (1.79–3.08)
Friedman Test T2 ¼ 36:15 T2 ¼ 31:14 T2 ¼ 2:87 T2 ¼ 4:03
Po0:0001 Po0:0001 P ¼ 0:043 P ¼ 0:011
Nebulised hypertonic saline in bronchiectasis 29
followed by IS, bricanyl and finally ACBT alone
(Friedman test T2 ¼ 31:14; Po0:0001).
Discussion
Following the initial insult that causes bronchiec-
tatic change, progression of disease is intimately
related to sputum retention, leading to a vicious
cycle of infection, inflammation and further spu-
tum production. Expectoration of sputum is, there-
fore, vitally important to limit disease progression.
This study has shown that in this selective group of
patients producing less than 10 g per day, an acute
beneficial treatment effect can be demonstrated.
Both nebulised IS and HS were significantly more
effective in increasing sputum yield, reducing
sputum viscosity and improving ease of sputum
expectoration when compared to ACBT alone.
However, HS was significantly better than IS, for
sputum weight, viscosity and ease of expectora-
tion.
Bricanyl, IS and HS significantly increased treat-
ment phase and total sputum weight compared to
ACBT alone. Direct application of bricanyl is known
to increase ciliary beat frequency, tracheal mucus
velocity, and whole lung clearance of airway
secretions Furthermore, Beta2 sympathomimetics
have been shown to stimulate ion transport and
water shift towards the airway lumen, possibly
increasing hydration. Thus the enhanced sputum
yield after the nebulisation of bricanyl may be due
to direct hydration or specific B2 adrenergic
stimulation or both mechanisms. The bronchodila-
tion that follows bricanyl may also aid the effec-
tiveness of physiotherapy, perhaps by increasing
effective expiratory flow rates or improving regio-
nal ventilation. However, comparison of the two
primary intervention groups (IS and HS) showed
that in all but two patients sputum weight
increased when treated with HS compared to IS.
The improvements in mucociliary clearance seen
following administration of HS may therefore result
from increases in the salinity of the retained
secretions, in particular, the gel surface where
improved interactions with cilia may result in
increased ciliary clearance.
Sputum viscosity significantly differed between
groups and was lowest in the HS phase. Clinically
this finding may be of great importance, as a
reduction in sputum viscosity will enhance the
effectiveness of sputum clearance. As a result
patients may find that chest clearance requires less
effort and is less tiring.
The reduction in sputum viscosity seen in this
study following HS support previous work suggest-
ing that sputum is saline dependent, and that the
nebulisation of HS has a direct effect on sputum
composition and visco-elasticity.2 The HS may have
achieved its effect by promoting hydration of
airway secretions in response to the osmotic
gradient created after the inhalation of HS.9 It
may also cause changes in ionic concentrations,
resulting in conformational changes that alter
rheologic properties of sputum and allow more
effective sputum clearance.10 These effects on
viscoelasticity are thought to be more likely
explanations rather than increases in ciliary activ-
ity.11 However the absolute mechanism responsible
for the observed benefits needs to be elucidated
with more certainty.
Increased sputum weight and reduced viscosity
were accompanied by an increased ease of ex-
pectoration. A significant difference was found
between each treatment phase, with the lowest
scores following HS. This implies that despite
producing more sputum patients find it easier to
expectorate, probably due to reduced viscosity.
Clinically this finding is important as if patients find
the sputum easier to expectorate; performing ACBT
will be easier, more effective and less tiring. This
may result in improved compliance.
Although only a secondary endpoint, spirometry
parameters were also measured. Because of the
small numbers comparison of HS and IS did not
demonstrate a significant difference, but overall a
trend for improving FEV1 from ACBT alone to
treatment produced a statistically significant and
arguably clinically significant improvement.
There have been no previous published reports of
the clinical effects of HS with bronchiectasis
patients but this study has shown that in stable
patients with low sputum yield, 7% HS is a well
tolerated, safe and easily administered adjunct to
physiotherapy airway clearance techniques and is
more effective than 0.9% IS. To allow application to
other patients with bronchiectasis the study needs
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Table 2 Chi2 comparison of sputum viscosity.
No sputum þ
Grades 1 and 2
Grades 3 and 4
ACBT 20 3
Terbutaline 20 3
IS 18 5
HS 9 14
Total Chi2¼ 18.18 (3df), P ¼ 0:0004:
Chi2 for linear trend ¼ 13.46 (1df), P ¼ 0:0002:
(Combined groups of (no sputum, grades 1 and 2) and
(grades 3 and 4) in each treatment phase).
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to be repeated in patients with different disease
severity’s who produce sputum volumes 410 g per
day. A prospective long-term study is now indicated
to determine its effectiveness on long-term infec-
tion rate, quality of life and lung function.
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